Everything we do at Oak Therapeutics is informed by thorough research. We therefore engage with external research partners, some of which are among the best in their fields. They help us to combine our technology expertise with the best available knowledge in medicine and patient care. We partner with institutions and individuals who believe in the mission of bringing affordable, high quality pharmaceuticals and nutraceuticals to underserved populations. Examples of our research collaborations include:



  • Children’s Hospital of Los Angeles: Development of antibiotics on Oral Dissolvable Strips (ODS) for pediatric cancer patients

  • University of Southern California: Absorption of Ivermectin on Oral Dissolvable Strips

  • University of Washington: Testing of an Aspirin Oral Dissolvable Strip for the emergency treatment of acute myocardial infarction.

Currently, we are also working on a project funded by the National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) for the development of an Isoniazid Oral Dissolvable Strip, an antibiotic used in the treatment of tuberculosis.


The contract enables us to develop a high-dose antibiotic Oral Dissolvable Strip (ODS) for children that is used in the treatment of tuberculosis. Tuberculosis (TB) is one of the world's deadliest diseases: Approximately one third of the world's population is infected with TB. In 2014, 9.6 million people around the world became sick with tuberculosis, and approximately 1.5 million people, many of them children, died. Our research and development will help the global fight against tuberculosis by improving patient adherence. 

Oak Therapeutics, Inc., 2029 Becker Drive, Lawrence, KS 66047, United States, Tel. +1-913-346-0990, Email: